Filing Details
- Accession Number:
- 0001209191-15-002245
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-01-06 16:45:21
- Reporting Period:
- 2015-01-02
- Filing Date:
- 2015-01-06
- Accepted Time:
- 2015-01-06 16:45:21
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1610876 | Jeffrey Chodakewitz | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp Gmda, Cmo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2015-01-02 | 2,291 | $73.51 | 86,791 | No | 4 | M | Direct | |
Common Stock | Disposition | 2015-01-02 | 100 | $119.03 | 86,691 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-01-02 | 1,200 | $122.35 | 85,491 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-01-02 | 991 | $123.12 | 84,500 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2015-01-02 | 2,291 | $0.00 | 2,291 | $73.51 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
45,835 | 2024-01-01 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $122.35 (range $121.75 to $122.74).
- Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $123.12 (range $122.78 to $123.33).
- The option vests in 16 quarterly installments from 01/02/2014.